

**Fig. S2. Supplemental data for TIMP3 and MMPs expression analysis.** (A) Concentration-dependent effect of Senexin B (24 h treatment) on TIMP3 or MMP3 expression (qPCR, in duplicates). (B) Effects of long-term treatment with 0.5 µM Senexin B for the indicated number of days on the expression of TIMP3, MMP3, MMP10 and MMP13 (qPCR, in duplicates). (C) Effects of in vivo treatment with Senexin B on the expression of TIMP3, MMP3, MMP10, MMP13 and CDK8 in hepatic metastases. Mice (n=6) received vehicle or Senexin B (33 mg/kg, p.o., b.i.d.) starting from the day of splenic inoculation of CT26 cells for 14 days. (D) RNA expression of TIMP3, MMP3, MMP10, and MMP13 in subcutaneous CT26 tumors (n=3) or in the intestine (n=3). (E) Comparison of relative expression levels of MMP3, MMP10 and MMP13 in intestines and s.c. CT26 tumors. \* denotes P<0.05, \*\* denotes P<0.01 and \*\*\* denotes P<0.001.